Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Charles River Laboratories International (CRL.N)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date Stock Price (US$) Price Target (US$) Rating
2022-02-28291.16420.00Buy
2022-05-04257.51378.00Buy
2022-08-23210.81260.00Buy
2023-02-26219.81255.00Buy
2023-09-21198.15250.00Buy
2023-11-08175.97215.00Buy
2023-12-14229.26270.00Buy
2024-02-14245.12290.00Buy
2024-08-07199.96240.00Buy
2024-11-06214.20250.00Buy
2025-01-16165.80185.00Neutral
2025-05-07136.97150.00Neutral

Disclosures

  • UBS beneficially owned 1% or more of a class of this company`s common equity securities as of last month`s end (or the prior month`s end if this report is dated less than 10 days after the most recent month`s end).
  • UBS Securities LLC makes a market in the securities and/or ADRs of this company.
  • UBS holds a long or short position of 0.5% or more of the listed shares of this company.
Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.